Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million a year earlier and a wider net loss of US$1.343 billion driven by litigation costs.

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports

Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.

Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to trade the catalyst.

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines. In the phase 4 double-blind,

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.

Moderna's first-quarter sales beat expectations, fueled by government deals outside the US and its first UK shipment under a long-term agreement.

Moderna (MRNA) shares surge 8% after Q1 revenue hits $389M, tripling year-over-year and beating estimates on strong international vaccine sales.